Director Keith S. Manchester filed a Form 4 with the SEC on November 18, 2026, disclosing sales of Roivant Sciences Ltd. common shares and in-kind distributions across three QVT-affiliated entities on November 16 and 17, 2026.

Key Highlights

  • Reporting person: Keith S. Manchester, listed as a Director of Roivant Sciences Ltd. (NASDAQ:ROIV).
  • Sales on November 16, 2026: 79,461 shares at $39.17 and 18,927 shares at $38.99 were disposed of from QVT Financial Investment Cayman Ltd.; 550,280 shares at $39.17 and 131,073 shares at $38.99 were disposed of from QVT P&E Roiv Hldgs Ltd.
  • Sales on November 17, 2026: 75,716 shares at $38.24 from QVT Financial Investment Cayman Ltd., 525,507 shares at $38.24 from QVT P&E Roiv Hldgs Ltd., and 798 shares at $38.24 from QVT Deferred Compensation Holdings Ltd.
  • In-kind distributions on November 17, 2026: QVT entities distributed 2,635,169 shares, 15,969 shares, and 385,620 shares respectively, coded as transaction type "J," for no consideration.
  • Post-transaction holdings: Following all reported transactions, QVT Financial Investment Cayman Ltd. held 13,499,093 shares, QVT Deferred Compensation Holdings Ltd. held 5,805,461 shares, and QVT P&E Roiv Hldgs Ltd. held 0 shares, all indirectly.
  • Beneficial ownership disclaimer: Manchester disclosed he has no voting or investment control over the QVT Entities and disclaims beneficial ownership except to the extent of his pecuniary interest.

Manchester Reports Multi-Day Share Disposals and In-Kind Distributions Across QVT Entities

According to the filing, all securities reported are held indirectly through three entities: QVT Financial Investment Cayman Ltd., QVT P&E Roiv Hldgs Ltd., and QVT Deferred Compensation Holdings Ltd. Manchester disclosed that he is a shareholder of each entity but "does not have any voting or investment control over the QVT Entities." The filing further states that "the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."

On November 16, 2026, the filing reported open-market sales coded "S" at prices of $39.17 and $38.99 per share from two of the QVT entities. On November 17, 2026, additional sales were reported at $38.24 per share. Also on November 17, the filing reports that "each of the QVT Entities made an in-kind distribution on a pro rata basis, for no consideration," covering 2,635,169 shares, 15,969 shares, and 385,620 shares across the three entities, coded as transaction type "J."

After all reported transactions, QVT P&E Roiv Hldgs Ltd. held zero remaining shares, while QVT Financial Investment Cayman Ltd. and QVT Deferred Compensation Holdings Ltd. retained 13,499,093 and 5,805,461 shares, respectively, all classified as indirect holdings. The filing was signed by Keith Manchester and dated November 18, 2026.

What Was Disclosed

Director Keith S. Manchester disclosed sales of Roivant Sciences common shares at prices ranging from $38.24 to $39.17 and in-kind distributions for no consideration across three QVT-affiliated entities on November 16 and 17, 2026, with all holdings classified as indirect.